Member Info for Aberdeenman

Reduced Risk Nuformix's approach uses existing drug molecules, with a history of safe use: No new safety data is required if staying within existing exposure limits, allowing rapid entry to both clinic and market Existing clinical data better informs decision making in future development Reduced time and cost of achieving clinical proof-of-concept and increasing success rates versus traditional biotech models NO NEW SAFETY DATA IS REQUIRED https://nuformix.com/pipeline/cocrystal-technology/strategic-benefits/

For those that are ignorant here... Regulatory Advantages Regulatory bodies treat drug cocrystals exactly as the pure drug: Drug substance has new physical properties only � its pharmacological activity is unchanged Therefore, drug cocrystals are applicable globally for both generic and abbreviated approval pathways US FDA Guidelines, April 2016: Cocrystals are classified as analogous to a new drug polymorph EMA Guidlines, May 2015: Cocrystals are treated as the same active substance as the original drug As the existing drugs are well known and have been around and in use for many years, having gone through many trials, the cocrystal version is deemed to be safe, and require minimal testing (24 hours tests on 12 volunteers') Very very clever, and will be very very valuable. First to market generics, with IP protection on the generic) in multi $B markets. https://nuformix.com/pipeline/cocrystal-technology/strategic-benefits/

Licencing/commercial deal due in months

From RNS - Early licensing revenues allow Nuformix to self-fund future discovery and development and build greater value into our pipeline

Well done all who bought before suspension Buying shells can be highly profitable Totally understand if selling, but hold a little back if you do. This is going to be worth a lot of money IMO

Maybe you should read more Commercial deal expected in next few months and long term will be bought out for more than $1b Most likely not many retail investors here anyway

And boy did they bite Been super fun This will rocket tomorrow, nothing said on here will change that

Should read No one reading this On my phone....

No one trading this really patch but those already invested and trolls Been having some fun baiting the trolls that is all

You are of course right patch, mistype But with so little overhead for this company they will have a very large margin Likely to be dividend paying if not sold within 24 months

*P/E ratio

Also worth noting the P/E ration for the drug industry is around 24 So recurring revenue of 41.67m will value this at £1B With a £Xm or £XXm deal in a few months, you dont need to be a world renowned scientist to work out where this is going. then NPX002!!! That is worth so much more Large pipeline of patents coming and very strong newsflow over the next few months LOVELY

*is first to market

To be fair Wress Merck produce lots, so cannot compare any market cap or share price. Would need to know earnings for their version, however the CEO says certainly for NPX002 it is a multi $B market, and health authorities worldwide are generally obliged to use a generic where available Nuformix if first to market in these generics and has IP protection

Thanks Wress What this company is doing is pure Genuis Hardly surprising with World renowned scientists on board One of the most exciting investments I have ever had

All systems are GO

Lol shite prophets could not spot a multibagger if it slapped them The are only interested in extorting money and free shares

Good luck Mr Robotic The trolls have been absolutely desperate to make sure you and about another one person reading this over the weekend who are not already invested, are saved from potentially 5 bagging or more tomorrow. LOL

Good that they already have patents covering China Wress. First commercial deal could come from there, already documented they expect it in a few months. will be worth �xm, price will fly on that one

Have a look at the Nuformix site. Trial takes one day, as per the CEO. I know you love this Inner REDUCED RISK Nuformix's approach uses existing drug molecules, with a history of safe use: No new safety data is required if staying within existing exposure limits, allowing rapid entry to both clinic and market Existing clinical data better informs decision making in future development Reduced time and cost of achieving clinical proof-of-concept and increasing success rates versus traditional biotech models NO NEW SAFETY DATA IS REQUIRED https://nuformix.com/pipeline/cocrystal-technology/strategic-benefits/